TXG
10x Genomics, Inc.
Medical - Healthcare Information Services
Market Cap$2.89B
5Y Perf.-71.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TXG vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
TXG vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TXG | DBVT |
|---|---|---|
| Industry | Medical - Healthcare Information Services | Biotechnology |
| Market Cap | $2.89B | $1712.35T |
| Revenue (TTM) | $643M | $0.00 |
| Net Income (TTM) | $-44M | $-168M |
| Gross Margin | 69.1% | — |
| Operating Margin | -9.5% | — |
| Total Debt | $158M | $22M |
| Cash & Equiv. | $474M | $194M |
TXG vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TXG
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| 10x Genomics, Inc. (TXG) | 100 | 28.8 | -71.2% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TXG vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TXG leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TXG
10x Genomics, Inc.
The Growth Play
TXG carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 5.2%, EPS growth 77.0%, 3Y rev CAGR 7.6%
- -57.5% 10Y total return vs DBVT's -87.0%
- 5.2% revenue growth vs DBVT's -100.0%
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.26
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TXG | 5.2% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs TXG's -6.8% |
| Stability / Safety | DBVT | Beta 1.26 vs TXG's 2.32, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TXG | +169.8% vs DBVT's +110.4% |
| Efficiency (ROA) | TXG | -4.4% ROA vs DBVT's -89.0% |
TXG vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
TXG vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTXGLAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
TXG10x Genomics, Inc.
1leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TXG4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TXG and DBVT operate at a comparable scale, with $643M and $0 in trailing revenue.
| Metric | TXG10x Genomics, Inc. | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $643M | $0 |
| EBITDAEarnings before interest/tax | -$29M | -$112M |
| Net IncomeAfter-tax profit | -$44M | -$168M |
| Free Cash FlowCash after capex | $130M | -$151M |
| Gross MarginGross profit ÷ Revenue | +69.1% | — |
| Operating MarginEBIT ÷ Revenue | -9.5% | — |
| Net MarginNet income ÷ Revenue | -6.8% | — |
| FCF MarginFCF ÷ Revenue | +20.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +0.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +67.5% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — TXG and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | TXG10x Genomics, Inc. | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $2.9B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $2.6B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -64.06x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 4.50x | — |
| Price / BookPrice ÷ Book value/share | 3.51x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 22.23x | — |
Evenly matched — TXG and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
TXG leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
TXG delivers a -5.7% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to TXG's 0.20x.
| Metric | TXG10x Genomics, Inc. | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -5.7% | -130.2% |
| ROA (TTM)Return on assets | -4.4% | -89.0% |
| ROICReturn on invested capital | -17.9% | — |
| ROCEReturn on capital employed | -13.1% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.20x | 0.13x |
| Net DebtTotal debt minus cash | -$316M | -$172M |
| Cash & Equiv.Liquid assets | $474M | $194M |
| Total DebtShort + long-term debt | $158M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -7374.83x | -189.82x |
TXG leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — TXG and DBVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $1,532 for TXG. Over the past 12 months, TXG leads with a +169.8% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs TXG's -25.6% — a key indicator of consistent wealth creation.
| Metric | TXG10x Genomics, Inc. | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +34.9% | +4.9% |
| 1-Year ReturnPast 12 months | +169.8% | +110.4% |
| 3-Year ReturnCumulative with dividends | -58.8% | +19.7% |
| 5-Year ReturnCumulative with dividends | -84.7% | -69.1% |
| 10-Year ReturnCumulative with dividends | -57.5% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -25.6% | +6.2% |
Evenly matched — TXG and DBVT each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TXG and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than TXG's 2.32 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TXG currently trades 84.8% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TXG10x Genomics, Inc. | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.32x | 1.26x |
| 52-Week HighHighest price in past year | $26.45 | $26.18 |
| 52-Week LowLowest price in past year | $7.72 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +84.8% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 53.0 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 252K |
Evenly matched — TXG and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TXG as "Hold" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -1.2% for TXG (target: $22).
| Metric | TXG10x Genomics, Inc. | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $22.14 | $46.33 |
| # AnalystsCovering analysts | 22 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 1 of 6 categories (Income & Cash Flow). TXG leads in 1 (Profitability & Efficiency). 3 tied.
Best Overall10x Genomics, Inc. (TXG)Leads 1 of 6 categories
Loading custom metrics...
TXG vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TXG or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TXG or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -84. 7% for 10x Genomics, Inc. (TXG). Over 10 years, the gap is even starker: TXG returned -57. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TXG or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus 10x Genomics, Inc. 's 2. 32β — meaning TXG is approximately 85% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 20% for 10x Genomics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TXG or DBVT?
On earnings-per-share growth, the picture is similar: 10x Genomics, Inc.
grew EPS 77. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TXG or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -6. 8% for 10x Genomics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -17. 2% for TXG. At the gross margin level — before operating expenses — TXG leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TXG or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TXG or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). 10x Genomics, Inc. (TXG) carries a higher beta of 2. 32 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, TXG: -57. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TXG and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.